Grigoris Gerotziafas: 3 ASH 2025 Poster Awards for Our Team!
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn:
”Three ASH 2025 poster awards for our team!
Proud to announce that three posters presented at the ASH 2025 Annual Meeting (Orlando, December 6–9, 2025) received awards
Abstract 1316: “Fibrin clot shields drive clonal selection of cancer cells: Procoagulant properties and proliferative survival of clot-embedded cancer cells. A novel model of tumor microenvironment remodeling.”
By Noelin Baskaran and Mohammed Baghdadi et al.
Abstract 1302: “Tissue factor bearing microparticles drive thromboinflammation and predict DIC and mortality in sepsis: Results from the ROADMAP-Sepsis study.”
Led by Patrick Van Dreden et al.
Abstract 2687: “Venous thromboembolism in multiple myeloma patients treated with BCMA-directed CAR T-cell therapy: A systematic review and meta-analysis.”
Led by Pedro Henrique Las Casas et al.
This success highlights the strength of our “Cancer Vessels, Biology and Therapeutics” (CaVITE) Research Team — a true dream team at the
Centre de Recherche Saint Antoine”
All from ASH25 featured in Hemostasis Today.
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH
-
Oct 18, 2026, 01:44Marta Velia Antonini: How to Deliver CRRT during ECMO?
-
Oct 18, 2026, 01:19Aamir Saeed: Anticoagulation, Cirrhosis, and Other Risk Factors for Post-ERCP Bleeding
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day